Re-modelling Drug Delivery Services for High-viscosity Formulations

International Biopharmaceutical Industry covers the latest in research, innovation and regulation, with each quarterly issue having a print copy distribution figure of 21,400.

Biologic formulations for subcutaneous delivery allow patients to self-administer their own treatment and reduce the need for them to consult hospital-based healthcare practitioners. Intravenous formulations are therefore being reformulated for subcutaneous injection (where possible) to capitalise on these benefits.

In this article, we look at the challenges faced by manufacturers and device engineers when adapting drug delivery devices to new biologic formulations and key strategies and developments within the industry to overcome these.